BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 8, 2001
View Archived Issues
Licensing opportunity from NIH: virus-like particles as unlinked adjuvants
Read More
Topically applied CDK2 inhibitor prevents chemotherapy-induced hair loss
Read More
Role of PPARs and their ligands in atherogenesis incites a flurry of research
Read More
Abgenix plans to move ABX-IL-8 into phase IIb clinical trials for psoriasis
Read More
Sepracor pharmaceutical products portfolio update
Read More
Lexicon Genetics and Abgenix establish drug target validation collaboration
Read More
Oxford BioMedica initiates phase I/II clinical trial of TroVax as treatment of colorectal cancer
Read More
Phase IIb study of TP-10 in infants undergoing high-risk cardiac surgery now under way
Read More
Anti-EGF MAb produces clinical, biochemical improvement in patient with Menetrier's disease
Read More
Elan prepares launch of Myocet in Europe
Read More
Vertex commences phase II trial of VX-745 for rheumatoid arthritis
Read More
Positive final results emerge from INS-1 trial for type 2 diabetes
Read More
Antiinflammatory and antiemetic effects of YM-976 evaluated in animal studies
Read More
Macrolide antimicrobial agents related to erythromycin prepared at Abbott
Read More
Selective inhibitors of cathepsin S designed jointly by Medivir and Peptimmune
Read More
Patent issued to Hokuriku covering new antibacterial series
Read More
CeNeS licenses North American rights for Moraxen to Amarin; additional phase III study planned
Read More
Sumitomo presents new ECE inhibitors and their potential uses
Read More
Naturally produced compounds with antiplatelet and other properties discovered by Teijin
Read More
New series of sphingomyelinase inhibitors described by Ono researchers
Read More
Phase II head and neck cancer trial of Multikine cleared in Mexico
Read More
Antiinflammatory compounds from Bayer act as PDE4 inhibitors
Read More
Marketing agreement with Bioglan for Solaraze expanded by SkyePharma
Read More
Phase II IDEC-131 study begins in patients with ITP
Read More
Generex and Elan to form joint venture
Read More
Amarillo Biosciences reports completion of IFN-alpha phase III trial in Sjogren's syndrome
Read More
University of Pittsburgh awarded NHLBI grant for cardiovascular gene therapy program
Read More